RFK’s Peptide Ruling: Where Things Stand in April 2026

In February 2026, HHS Secretary Robert F. Kennedy Jr. made a landmark announcement on the Joe Rogan Experience: approximately 14 of the 19 peptides placed on the FDA’s Category 2 restricted list in 2023 would be moved back to Category 1 — restoring legal access through licensed compounding pharmacies with a physician’s prescription.

It was the biggest shift in peptide regulation in years. But as of April 2026, the formal FDA reclassification has not been published. Here’s where things actually stand.

What RFK Announced

On February 27, 2026, Kennedy stated that the FDA would move roughly 14 of the 19 restricted peptides back to Category 1 status — meaning compounding pharmacies could once again prepare them legally under physician prescription. The announcement generated widespread coverage and significant optimism across the peptide research community.

The peptides widely expected to return to legal compounding status include BPC-157, TB-500, Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, GHK-Cu, and several others that were pulled from compounding pharmacy shelves in 2023.

What Hasn’t Happened Yet

The announcement was a statement of intent — not a regulatory action. For the reclassification to take effect, the FDA must formally publish an updated list of Category 1 bulk drug substances. That paperwork has not appeared.

Compounding pharmacies are in a holding pattern. Many are preparing to resume peptide compounding as soon as written guidance is issued, but most are waiting for explicit FDA clearance before filling orders. Until the formal list is published, the Category 2 designations remain in effect.

It is also important to understand what reclassification does and does not mean. Moving a peptide from Category 2 to Category 1 restores its eligibility for compounding under physician prescription — it does not constitute FDA approval. Compounded peptides would still require a valid prescription, still lack formal FDA approval as finished drug products, and still carry no standardized dosing guidelines.

Why the Delay Matters

The gray market fills the gap. Since the 2023 restrictions, researchers have largely turned to vendors selling peptides labeled “for research use only” — the category that Prof. Peptide’s vetted vendor network operates in. Demand has not decreased; it simply moved outside the compounding pharmacy system.

When the formal reclassification does arrive, compounding pharmacies will need time to source pharmaceutical-grade ingredients and ramp up production. Industry groups have warned that even after a formal announcement, supply through compounding channels may take weeks or months to stabilize.

What to Watch For

The FDA’s formal updated bulk drug substance list is the key document to watch. When it is published, it will confirm exactly which of the 19 peptides are moving to Category 1, the timeline for compounding pharmacies to begin preparations, and any conditions or requirements attached to the reclassification.

Prof. Peptide will update this article as developments occur.